Percutaneous Dilational Tracheostomy in Patients Receiving Antiplatelet Therapy

Antiplatelet agents have become a mainstay therapy for vascular diseases; yet, it increases the risk of bleeding. The latter has a potential to impact the safety of invasive procedures. A retrospective chart review of patients undergoing percutaneous dilational tracheostomy (PDT) at each of the 2 institutions was performed to determine the bleeding risk for patients on antiplatelet therapy who underwent PDT. Out of the 246 patients who underwent PDT over the study period, 20 qualified for the study group. All were being treated with clopidogrel. A control group of 137 patients was created. No major bleeding occurred in either of the group. Minor bleeding occurred in 1 study patient (5%) and in 5 (3.6%) of the control patients (P=0.85). The data support the performance of PDT without stopping clopidogrel if there was a clear and ongoing indication for the antiplatelet agent.